Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.

European journal of haematology(2023)

引用 0|浏览10
暂无评分
摘要
In conclusion, long-term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.
更多
查看译文
关键词
BNT162b2, booster dose, cellular immune response, humoral immune response, lymphoid malignancies, myeloid malignancies
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要